Addressing the diversity challenge in clinical trials
Solving the challenge of increasing minority participation in clinical trials requires a long-term commitment and investment from the research community.
25th April 2019
Web Exclusives
Nothing less than a bleed-free life
To mark World Haemophilia Day, Laurence Woollard talks to PharmaTimes about engaging today’s generation of young people living with the condition to advocate for nothing less than a bleed-free life
17th April 2019
Lonely at the top?
Ex England cricketer Jeremy Snape says pharma leaders looking to inspire their teams during volatile times should see what lessons they can learn from other industries faced with similar challenges
15th April 2019
The search for a cure for Alzheimer’s is far from over
Patent-mapping research suggests that innovation-led newcomers may already be on to something new
28th March 2019
AI and pharma sales
Alex Dale looks at where we are with AI and how it might help pharma sales
28th March 2019
Sanofi's Hugo Fry talks Brexit
Sanofi UK's managing director Hugo Fry shares his thoughts on Brexit
26th March 2019
Unlocking the UK’s virtual drug discovery capability
The UK is well positioned to take advantage of virtual drug discovery services, says Medicines Discovery Catapult's Graeme Wilkinson
11th March 2019
The Amazon effect
The pharma industry needs to transform the supply chain from a source of regulatory risk to a legitimate business opportunity.
11th March 2019
Preparing your workforce for Brexit
Trouble on the horizon for pharma? A look at post-Brexit immigration.
21st February 2019
The rise of virtual pharma
The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.
11th February 2019
Medical devices regulation countdown
Cliodhna McDonough says new regulations on the horizon for medical devices in Europe present a huge challenge to manufacturers, but could also deliver improved confidence in the consistency and effectiveness of the regulatory process.
11th February 2019
The SPC eligibility issue
The European Court should prepare for legal challenges to the ineligibility of new medical technologies for Supplementary Protection Certificates (SPCs).
23rd January 2019
Redefining Value
In today’s highly competitive healthcare market how can pharma companies stand out from the crowd? Showing brand value has never been more important.
23rd January 2019
The controversy over gene-editing
CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.
10th January 2019
Unlocking sci-tech growth in the UK
The health of the life sciences sector in 2019 will continue to be a major focus as the UK navigates all the issues surrounding Brexit.
7th January 2019
